Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Subscribe Now!

Administration of FDA-Approved Fecal Microbiota Transplants for C. difficile Infections in Clinical Practice

EP: 1.Epidemiology of C. difficile Infections in the US

EP: 2.Recurrence of C. Difficile Infections

EP: 3.Risk Factors for C. difficile Infections

EP: 4.Patients at Risk for Recurrent C. difficile Infections and the Role of Environmental Factors

EP: 5.Diagnostic Tests for C. difficile Infections

EP: 6.Treatment Guidelines for C. difficile Infection

EP: 7.Factors Contributing to C. difficile Infection Recurrence

EP: 8.Managing C. difficile Infections in the Clinic

EP: 9.Contribution of Unnecessary and Prolonged Antibiotic Use to Recurrent C. difficile Infections

EP: 10.Fecal Microbiota Transplantation for C. difficile Infections

EP: 11.Recent Fecal Microbiota Transplant Approvals for C. difficile Infections

EP: 12.Administration of FDA-Approved Fecal Microbiota Transplants for C. difficile Infections in Clinical Practice

EP: 13.Data on Fecal Microbiota, Live-JSLM (RBL) for C. difficile Infections

EP: 14.ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections

EP: 15.Safety of Fecal Microbiota Options and Transfer of Food-Borne Allergens

EP: 16.Utilization of Fecal Microbiota Transplant Products in Clinical Practice

EP: 17.Physicians’ Use of Fecal Microbiota Transplant for Recurrent C. difficile Infections

EP: 18.Tips for Talking with Patients about Fecal Microbiota Transplant for Recurrent C. difficile Infections

Newsletter